Shanxi Coking Coal Energy Group (000983.SZ) has suspended production at the Xiqu Mine due to an accident.
Shanxi Coking Coal (000983.SZ) announced that a safety production accident occurred at its subsidiary, Xiqu Mine, on August 5, 2026, resulting in one fatality. The Xiqu Mine has now suspended production, and relevant government departments are conducting an investigation to ascertain the cause of the accident. The Xiqu Mine is a subsidiary of the company, with an annual approved production capacity of 2.7 million tons, accounting for 5.67% of the company's total approved production capacity. Following the accident, the Xiqu Mine is actively cooperating with the accident investigation and strengthening safety risk management and hazard identification and rectification. The specific impact of this production suspension on the company's operating data will be determined based on the company's subsequent audited financial reports.
Shanxi Coking Coal Energy Group (000983.SZ) announced that a safety production accident occurred at its subsidiary, the Xiqu Mine, on August 5, 2026, resulting in one fatality. The Xiqu Mine has since ceased operations, and relevant government departments are conducting an accident investigation. The Xiqu Mine, a subsidiary of the company, has an annual approved production capacity of 2.7 million tons, accounting for 5.67% of the company's total approved capacity. Following the accident, the Xiqu Mine is actively cooperating with the investigation, enhancing safety risk management, and conducting hazard identification and remediation. The specific impact of this production suspension on the company's operational data will be determined based on the company's subsequent audited financial reports.
Related Articles
Merck & Co., Inc. (MRK.US) has submitted its oral drug for the treatment of AIDS for market approval in China.
Guangdong Create Century Intelligent Equipment Group Corporation (300083.SZ) plans to implement an employee stock ownership plan in 2026.
Takeda (TAK.US) has received approval from the U.S. FDA for Oxybate for the treatment of type 1 narcolepsy.
Merck & Co., Inc. (MRK.US) has submitted its oral drug for the treatment of AIDS for market approval in China.
Guangdong Create Century Intelligent Equipment Group Corporation (300083.SZ) plans to implement an employee stock ownership plan in 2026.
Takeda (TAK.US) has received approval from the U.S. FDA for Oxybate for the treatment of type 1 narcolepsy.
RECOMMEND
